Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting ID
Varian Medical Systems (Industry)

Study Details

Study Description

Brief Summary

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.

This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy.

In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.

Detailed Description

This is a feasibility/pilot study of 5 Gy adaptive radiation administered every 5 business days (1 week apart) for 5 weeks prior to standard of care CAR T-cell therapy infusion. Approximately 10 participants with Relapsed/Refractory B-cell Lymphoma will take part in this research study. The primary objective is to assess the feasibility of once weekly radiation therapy for 5 weeks.

Study Design

Study Type:
Anticipated Enrollment :
10 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
5-5-5 Adaptive Bridging Radiation Therapy (ABRT) for Relapsed/Refractory B-cell Lymphoma Prior to CAR T-cell Therapy
Anticipated Study Start Date :
Feb 14, 2024
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: 5-5-5 Adaptive Bridging Radiation Therapy (ABRT)

5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion

Radiation: Adaptive Bridging Radiation Therapy (ABRT)
Radiation Therapy

Outcome Measures

Primary Outcome Measures

  1. Feasibility [20 months]

    Feasibility is being measured based on the percentage of patients being able to undergo ABRT

Secondary Outcome Measures

  1. Adverse Events [20 months]

    Adverse events will be classified and graded according to the CTCAE v.5.0.

  2. Objective Response Rate (ORR) [15 months]

    ORR is being measured using the day 30 and day 90 PET scans and assessed by Lugano lymphoma response criteria

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Diagnosis of relapsed or refractory B-cell lymphoma (including, but not limited to diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from follicular lymphoma, follicular, and mantle cell lymphoma)

  • Being planned to undergo CAR T-cell therapy (patients can be enrolled prior to apheresis)

  • At least 1 measurable lesion according to the Lugano criteria35. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. Re-irradiation is allowed for these patients. More than 1 lesion can be targeted as per radiation oncologist discretion. If disease is palpable, physical examination alone may be sufficient measurement for disease if a recent PET/CT or CT is not available as a radiologic measurement of the disease can be obtained during CT simulation.

  • Age ≥ 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to

  • Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
  • Any medical condition likely to interfere with assessment of safety or efficacy of RT.

  • CNS-only disease as the site for bridging radiation therapy (which cannot be reliably evaluated on CT). Patients with CNS disease with extra-axial involvement that can be evaluated on CT remain eligible.

  • Patient likely unable to lay supine for 45 minutes

  • Women of child-bearing potential who are pregnant because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential

  • In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

Contacts and Locations


Site City State Country Postal Code
1 Dana-Farber Cancer Institute Boston Massachusetts United States 02215

Sponsors and Collaborators

  • Massachusetts General Hospital
  • Varian Medical Systems


  • Principal Investigator: Chirayu Patel, MD, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Chirayu G. Patel, Principal Investigator, Massachusetts General Hospital Identifier:
Other Study ID Numbers:
  • 23-364
First Posted:
Aug 22, 2023
Last Update Posted:
Aug 22, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Chirayu G. Patel, Principal Investigator, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2023